Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

C2N Diagnostics Receives FDA 510(k) Clearance for Alzheimer's Blood Test

20 August 2026 · By · Wire by Fusion42

Published

20 August 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at 360dx.com →

◆ Verified

Fusion42 · 20 August 2026 · Fusion42 review

C2N Diagnostics has received FDA 510(k) clearance for its PrecivityAD2 blood test that detects Alzheimer's disease, enabling wider clinical adoption in the United States.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 13 sources have reported it between 20 Aug 2026 and 26 Sep 2026.

◆ ◆ The Wire takeaway

You now have a clearer regulatory path to bring blood-based Alzheimer's diagnostics to US clinics. This opens opportunities to partner with health systems eager for earlier, easier testing.

◆ Coverage

13 sources · first reported 20 Aug 2026 · latest 26 Sep 2026

◆ Related on Wire

◆ Topics

Diagnosticsfda-clearancealzheimersblood-testdiagnosticsregulatory-approval